335 related articles for article (PubMed ID: 16680735)
1. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
Elice F; Raimondi R; Tosetto A; D'Emilio A; Di Bona E; Piccin A; Rodeghiero F
Am J Hematol; 2006 Jun; 81(6):426-31. PubMed ID: 16680735
[TBL] [Abstract][Full Text] [Related]
2. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
5. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
6. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
8. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
[TBL] [Abstract][Full Text] [Related]
9. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M
J Clin Oncol; 2007 Jun; 25(17):2434-41. PubMed ID: 17485707
[TBL] [Abstract][Full Text] [Related]
10. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
[TBL] [Abstract][Full Text] [Related]
13. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
14. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
[TBL] [Abstract][Full Text] [Related]
15. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.
Krejci M; Buchler T; Hajek R; Svobodnik A; Krivanova A; Pour L; Adam Z; Mayer J; Vorlicek J
Bone Marrow Transplant; 2005 Jan; 35(2):159-64. PubMed ID: 15543200
[TBL] [Abstract][Full Text] [Related]
17. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
Kumar L; Ghosh J; Ganessan P; Gupta A; Hariprasad R; Kochupillai V
Bone Marrow Transplant; 2009 Mar; 43(6):481-9. PubMed ID: 18978818
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
20. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]